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Clinical features of patients with heart failure and renal dysfunction
Fatima Arhlade, Amina Asadi, Safaa Raboukhi, Rachida Habbal
CHU Ibn Rochd, Cardiologie, Casablanca, Maroc
Background: Because renal function is affected by chronic heart failure
(CHF) and it relates to both cardiovascular and hemodynamic properties, it
should have additional prognostic value. We studied whether renal function is
a predictor for clinical outcomes CHF and relation to echocardiographic
parameters in these patients.
Methods and Results: The study population consisted of 1284 patients
with CHF. The glomerular filtration rate (GFR) was calculated using the
Modification of diet in renal disease (MDRD). We divided Patients on
4 groups: GFR>60ml/min/1,73m2 (group 1=296 patients, 23%), 30Mean
GFR in severe RD patients was 9.44±3,59ml/min/1,73m2 (group 4),
24.6±3.59 in group 3, 46.3 ± 7.8 in group 2 and 73.4±15.7 in group 1.
Compared to 296 (23%) patients with preserved GFR, they had more co-
morbidities and more frequently ischemic etiology of HF.
Patients with renal insufficiency had low functionnal capacity during six
minute walking, more left bundle branch block (p<0.00001), more left ventri-
cular hypertrophy (p=0.02), more systolic dysfonction and more Increased E/
A (p<0.00001).
Beta-blockers were used less frequently in those patients (p<0.00001) who
receive high dose of diuretic (p<0.00001), ACE (p<0.00001) and amiodarone
(p<0.01).
Conclusions: Renal insufficiency is more prevalent in patients with heart
failure and is prognostic factor in functional capacity, diastolic and systolic
dysfunction.
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Impact of elevated heart rate on clinical outcomes in patients with
heart failure with reduced ejection fraction
Amina Asadi, Fatima Arhlade, Zineb Benchaouia, Rachida Habbal,
Rachida Habbal
CHU Ibn Rochd, Cardiologie, Casablanca, Maroc
Background: Elevated heart rate (HR) is associated with higher mortality
and morbidity in patients with heart failure (HF). This study is aimed to eva-
luate the clinical significance of heart rate in predicting the prognosis in
patients with chronic heart failure (CHF).
Methods: We enrolled 1581 consecutive CHF (mean age 68.1 years) reg-
istered in the Therapeutic Unit of Chronic Heart Failure. We divided the
patients into 2 groups: group 1 with HR≤70 bpm, group 2 with HR >70 bpm.
The relationships between HR and the prognosis of CHF patients were deter-
mined.
Results: Elevated HR was associated with male sex, hypertension, dia-
betes, strock attack and ischemic heart disease, but the association was modest
with obesity. CHF patients with NYHA grade III/IV had higher HR than those
with NYHA grade I/II with a good correlation. Hight HR correlated with
increased cardiac decompensation and hospitalizations (p<0.0001), elevated
filling pressure (p<0.0001). Also, there were statistical differences in atrial
fibrillation between the group 1 and 2. Furthermore, ?-Blocker therapy and
Ivabradine were associated with reduced HR (p<0.0001). We also observed
negative correlations between HR and hemoglobin, glomerular filtration rate
(GFR) were also found.
Conclusions: Elevated HR was associated with increased cardiac decom-
pensation and hospitalization. It may have good clinical predictive value in
patients with CHF and should be a distinct therapeutic target.
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Analysis of electrocardiographic abnormalities in chronic heart fai-
lure: about 1622 cases (UTIC registry)
Hafdi Karim, Salim Arous, Adolphe Kasongo, Rachida Habbal
CHU Ibn Rochd, Cardiologie, Casablanca, Maroc
Introduction: The electrocardiogram (ECG) is an important tool in the ini-
tial evaluation of patients with congestive heart failure and in the monitoring
of these patients. The purpose of this work is to describe the different electro-
cardiographic abnormalities encountered in patients monitored for chronic
heart failure.
Methods: A retrospective study of major electrocardiographic abnormali-
ties, involving 1622 patients with chronic heart failure, followed in the heart
failure processing unit (UTIC) of UH Ibn Rochd of Casablanca, between
January 2008 and October 2014.
Results: The mean age of patients was 68.6 years (± 12 years, ranging
from 18 to 104 years), with a sex ratio of 1.67. The main cardiovascular risk
factors identified were: hypertension (46.1%), diabetes (38.8%), tobacco
(38.6%) and dyslipidemia (14.9%) cases. The etiology of heart fealure was in
order of frequency: ischemic heart disease (55.6%), DCM (27.5%), hyperten-
sive heart disease (9.8 %) and valvulopathy (5.7%). The major éléctrocar-
digraphique abnormalities were: repolarization disorders (41.9%), the Q wave-
necrosis (18.7 %) and atrial fibrillation (11.8%). The conduction disorders
have been dominated by the left bundle branch block (23.9 %), followed by
the first atrio-ventricular block (11.02%). The signs of cavitary hypertrophy
was noted especially on the left side: left ventricular hypertrophy was
observed in 11.4% of cases, while the left atrial hypertrophy was observed in
3.3 % of cases. Recorded rhythm disorders had been dominated by the atrial
fibrillation (11.8%) followed by the ventricular rhythm disorder (8.8%).
Conclusion: Electrocardiographic abnormalities are common in patients
with chronic heart failure and a normal ECG must review the diagnosis. The
conrol of rhythm disorders and prevention of its complications is a major
pillar in the management of chronic heart failure.
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The impact of diurnal fasting during Ramadan on patients with chro-
nic heart failure
Faïrouz Haloui, Noura Elazaoui, Rachida Habbal
CHU Ibn Rochd, Cardiologie et maladies vasculaires, Casablanca, Maroc
Objective: To determine the clinical and biochemical effects of fasting
during Ramadan on patients with chronic heart failure.
Methods: Fifty-three outpatients with chronic heart failure with intention
to fast were studied in the month of Ramadan 2014 (1435 Hijri) at the Cardi-
ology departement in Ibn Rochd University hospital, Casablanca, Morocco.
Detailed clinical and biochemical assessments were performed within one
week before the start of Ramadan and then on the last day of Ramadan.
Results: There were 31 (58.5%) males and 22 (41.5%) females with a
mean age of 60±11 years (range, 34-88). Thirty eight patients (71.1%) had
coronary artery disease, 10 patients (18.9%) had dilated cardiomyopathy,
2 patients (3.8%) had valvular heart disease, one patient (1.9%) had toxic car-
diomyopathy secondary to chemotherapy, one patient had hypertensive cardio-
myopathy and another patient had Meadows cardiomyopathy. Forty-two
patients (79.2%) were in New York Heart Association (NYHA) Class I,
11 patients (20.8%) in Class II. Forty-nine patients (92.4%) managed to fast
during the entire Ramadan, 4 patients (7.5%) missed the fasting for up to
10 days. There were no significant changes in the NYHA Class (p= 0.18) nor
there were any significant changes in the Canadian Cardiac Society (CCS)
class in patients with coronary artery disease (p=0.09). No significant changes
occurred in any of the hematological or biochemical parameters during the
fasting of Ramadan.
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Conclusion: The effects of fasting during Ramadan on stable patients with
chronic heart failure are minimal. The majority of patients with stable cardiac
disease can fast during Ramadan without significant detrimental effects.
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Evaluation of management of heart failure and sleep apnea syndrome
in a cardiac intensive care unit
Sonia Houssany (1), Nicolas-Charles Roche (2)
(1) Hôpital d’instruction des armées Percy, Clamart, France – (2) Hôpital
d’instruction des armées Begin, Saint Mandé, France
Background: Sleep apnea syndrome (SAS) is seen in approximately 40%
of patients with congestive heart failure. SAS is also associated with an
increased mortality in patients with systolic heart failure. The aim of this work
was to evaluate the screening for SAS in patients hospitalized for acute
congestive heart failure in a cardiac intensive care unit.
Method: We performed a single-center retrospective study of patients hos-
pitalized for congestive heart failure with altered left ventricular ejection frac-
tion (lvef) ≤45% from june to december 2013. We assessed the screening for
sleep apnea syndrom using Epworth sleepiness scale.
Results: We included 51 patients. Mean values were for age 76 y. o, men
54%, body mass index 27kg/m², lvef 32%, diabetese 34%, hypertension 40%,
NYHA III 38% and NYHA IV 50%. Only 14% (7) of patients were screened
for SAS using the Epworth scale. All of them benefited a polysomnography at
less one month after discharge. 6 of them (85%) were diagnosed with SAS.
Conclusion: Although Epworth scale is a usefull and easy tool, Apnea
syndrom remains underdiagnosed. Because of its high prevalence, poor out-
come, and the beneficial effects of treatment, cardiologist should be more
aware of SAS
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RadiothErapy for BrEast Cancer and early detection of CArdiotoxi-
city (REBECCA): a prospective cohort study
Sophie Jacob (1), Carole Massabeau (2), Olivier Lairez (3), Hervé Rousseau
(4), Matthieu Berry (5), Stéphane Gellée (4), Fabien Milliat (6), Radia
Tamarat (7), David Broggio (8), Sylvie Derreumaux (9), Luc Simon (2),
Marc Benderitter (10), Marie-Odile Bernier (11), Jean Ferrières (12)
(1) IRSN, PRP-HOM/SRBE/Laboratoire d’Epidémiologie, Fontenay-Aux-
Roses, France – (2) Institut Universitaire du Cancer Toulouse-Oncopole,
Toulouse, France – (3) CHU Toulouse Rangueil, Centre d’imagerie car-
diaque, Toulouse, France – (4) CHU Toulouse Rangueil, Radiologie, Tou-
louse, France – (5) CHU Toulouse Rangueil, Cardiologie, Toulouse,
France – (6) IRSN/PRP-HOM/SRBE/Laboratoire de Recherche en Radio-
biologie et Radiopathologie, Fontenay-Aux-Roses, France – (7) IRSN/
PRP-HOM/SRBE/ Laboratoire de recherche en régénération des tissus
sains irr, Fontenay-Aux-Roses, France – (8) IRSN/PRP-HOM/SDI/Labo-
ratoire d’Evaluation de la Dose Interne, Fontenay-Aux-Roses, France –
(9) IRSN/PRP-HOM/SER/Unité d’Expertise en radioprotection Médicale,
Fontenay-Aux-Roses, France – (10) IRSN/PRP-HOM/SRBE, Fontenay-
Aux-Roses, France – (11) IRSN, PRP-HOM/SRBE/Laboratoire d’Epide-
miologie, Fontenay Aux Roses, France – (12) CHU Toulouse Rangueil,
Epidémiologie, INSERM UMR 1027, Toulouse, France
Breast radiotherapy (RT) techniques used until the 1990s were respon-
sible for increased mortality due to long term cardiac complications. Since
the 2000s, improved techniques of RT have appeared leading to different
dose distributions to organ at risks such as heart. But up to now, little is
known on their cardiac toxicity. The aim of the REBECCA study is to eval-
uate whether helical tomotherapy (HT) induces cardiac toxicity that could be
detected in the first two years after treatment based on analysis of sub-
clinical functional and anatomical cardiac lesions at myocardial and coro-
nary levels and evolution of circulating biomarkers. REBECCA study is a
prospective cohort study that will include 120 women treated with adjuvant
HT for breast cancer at the Institut Universitaire du Cancer Toulouse-Onco-
pole (IUCT), and followed up for 2 years after RT. Women aged 40 to
70 years, surgically treated at IUCT for breast cancer and for whom adjuvant
RT with HT is indicated, without chemotherapy will be eligible for the
study. Follow-up will include measures of a panel circulating biomarkers,
coronary plaque index based on Coronary computed tomography angio-
graphy and myocardial strain based on 2D-speckle tracking echocardiog-
raphy. Absorbed doses will be evaluated for the whole heart and for each
different parts of heart, in particular coronary arteries. Analysis will focus
on dose-response relationship between subclinical cardiac lesions, bio-
markers, and different organ absorbed doses. Furthermore, this study aims
to create a bio-bank of plasma and blood of this cohort for future investiga-
tions. This clinical research study is a novel approach to early detect cardio-
toxicity of current breast RT, combining anatomical and functional heart
consequences based on cardiac imaging, a panel of circulating biomarkers
and a detailed heart dosimetry. With this approach, REBECCA aims to
improve understanding of the mechanisms and circumstances that underlie
the development of potential heart side effects and sequelaes.
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Clinical, epidemiological and etiological characteristics of pulmonary
hypertension and its prognostic value in chronic systolic heart failure:
a report from the Ibn Rochd-HF Registry
Fatimazahra Sabri, Fatima Arhlade, Mariam Abelhad, Amina Asadi,
Rachida Habbal
CHU Ibn Rochd, Cardiologie, Casablanca, Maroc
Purpose: Pulmonary hypertension (PH) is a predictor of mortality and
morbidity in patients with chronic heart failure (HF) but it is poorly described
in our population. We sought to study, the prevalence, determinants, and prog-
nostic significance of PH in a large representative population with HF.
Methods: We retrospectively studied 1613 patients with HF. Systolic pul-
monary artery pressure PASP was determined by echocardiography, PH was
defined as PAPS> 50 mmHg.
Results: The proportion of patients with PASP>50mm Hg was:
12,15%(196/1613),with an average age of 69 years, there was 40,30% women
and 59,70% men, 96,43% of patients had low LVEF( left ventricular ejection
fraction) and only 1,02% had preserved LVEF. The ischemic etiology of HF
was predominant (17,86%).Most patients were receiving diuretics (66,33%),
beta-blockers (58,16%) and ACE inhibitor (86,22%), whereas 55, 10% were
on Spironolactone. The etiology of PH was mostly due to the left heart dis-
ease, while 1.02% was due to primary HP and 2.04% patient had COPD
(Chronic obstructive pulmonary disease). Patients with PH had a rate of
6.06% of AHFD (acute heart failure decompensation) occurrence. we note that
patients with both PH and RV dysfunction had a greater risk of AHFD
(14.28%).
Conclusion: PH is common in HF patients, associated with worse LV
function and provide incremental prognostic informations. The combination of
PH and RV dysfunction is particularly ominous. Thus, the estimation of PASP
should be considered in the standard assessment of ambulatory HF patients
and we must study it as a therapeutic way in this population
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Long-term cardiac prognosis and risk stratification in 260 adults pre-
senting with mitochondrial diseases
Karim Wahbi (1), Wulfran Bougouin (1), Anthony Behin (2), Tanya Stojko-
vic (2), Henri-Marc Bécane (2), Claude Jardel (2), Nawal Berber (2), Anne
Lombès (3), Bruno Eymard (2), Denis Duboc (1), Pascal Laforet (2)
(1) APHP-Hôpital Cochin, Paris, France – (2) APHP-GH Pitié-Salpê-
trière, Paris, France – (3) APHP-Hôpital Cochin, INSERM, UMRS 975,
Paris, Paris, France
Background: The long-term cardiac prognosis of adults with mitochon-
drial diseases is unknown.
Methods and Results: Between January 2000 and May 2014, we retro-
spectively included in this study 260 consecutive patients (60% women)
≥18 years of age, [interquartile range (IQR) = 31 to 54], with genetically
proven mitochondrial diseases, including 109 with mtDNA single large-scale
deletions, 64 with the m.3243A>G mutation in MT-TL1, 51 with other
